Effects of moxonidine and combination of moxonidine and ivabradine on insulin resistance in patients with metabolic syndrome
Kazan medical journal · 2015
DOI: 10.17750/kmj2015-032 ↗Kurz gefasst
Fachartikel in der Zeitschrift Kazan medical journal, 2015. Verfasst von M N Azimova und 3 weiteren Autor:innen. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).
Abstract (Originalsprache)
Aim
To explore the features of insulin resistance variations in overweight and obese patients with metabolic syndrome treated with moxonidine and combination of moxonidine and ivabradine.
Methods
The study included 30 patients with metabolic syndrome, who were overweight (body mass index 26.9±0.2 kg/m2) and 30 patients with metabolic syndrome and obesity (BMI 34.2±0.3). Control group included 17 healthy volunteers matched with patients by age and sex. Patients with metabolic syndrome and excessive body weight received moxonidine twice daily in average daily dose of 0.58±0.07 mg. Patients with metabolic syndrome and obesity received moxonidine twice daily in average daily dose of 0.52±0.04 mg and ivabradine twice daily in average daily dose of 13.7±1.1 mg. Biochemical blood tests (insulin, C-peptide, glucose, glycated hemoglobin serum levels) were performed in all patients.Results.Patients with metabolic syndrome and obesity tended to increase insulin resistance, compared to individuals with metabolic syndrome and excessive body weight. In overweight patients with metabolic syndrome treated with moxonidine, a trend for lower insulin resistance, accompanied by a decrease of insulin, C-peptide, glycosylated hemoglobin, glucose levels and homeostasis model assessment-estimated insulin resistance (HOMA-IR) index by 7.1, 2.0, 5.0, 7.3 and 12.2% respectively was discovered. Combination therapy with moxonidine and ivabradine in patients with metabolic syndrome and obesity leaded to a statistically significant improvement of insulin resistance, accompanied by a decrease of insulin levels, glucose, C-peptide, and glycated hemoglobin by 16.7%, 12.3% (pConclusion. In patients with metabolic syndrome, deepening of insulin resistance on the background of increased sympathetic activity is associated with higher grades of obesity. Combination therapy with moxonidine and ivabradine in patients with metabolic syndrome and obesity leads to a significant improvement in insulin resistance due to the additional sympatholytic effect.
Zitieren
APA
Azimova, M. N., Bakhshaliev, A. B., Kakhramanova, S. M., & Dadashova, G. M. (2015). Effects of moxonidine and combination of moxonidine and ivabradine on insulin resistance in patients with metabolic syndrome. Kazan medical journal. https://doi.org/10.17750/kmj2015-032
Vancouver
Azimova MN, Bakhshaliev AB, Kakhramanova SM, Dadashova GM. Effects of moxonidine and combination of moxonidine and ivabradine on insulin resistance in patients with metabolic syndrome. Kazan medical journal. 2015. doi:10.17750/kmj2015-032
BibTeX
@article{Azimova2015,
author = {Azimova, M N and Bakhshaliev, A B and Kakhramanova, S M and Dadashova, G M},
title = {Effects of moxonidine and combination of moxonidine and ivabradine on insulin resistance in patients with metabolic syndrome},
journal = {Kazan medical journal},
year = {2015},
doi = {10.17750/kmj2015-032}
}
EUVIMED